TRCT
DNTH icon

Tower Research Capital (TRC)’s Dianthus Therapeutics DNTH Stock Holding History

Tower Research Capital (TRC)’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180K Sell
1,845
-2,946
-61% -$257K ﹤0.01% 1773
2026
Q1 		$402K Buy
+4,791
New +$277K 0.01% 1078
2025
Q4 		– Sell
-1,443
Closed -$56.8K – 5236
2025
Q3 		$56.8K Sell
1,443
-2,877
-67% -$73.5K ﹤0.01% 2428
2025
Q2 		$80.5K Buy
4,320
+3,317
+331% +$62.2K ﹤0.01% 2560
2025
Q1 		$18.2K Sell
1,003
-376
-27% -$8.29K ﹤0.01% 3057
2024
Q4 		$30.1K Sell
1,379
-944
-41% -$24.3K ﹤0.01% 2903
2024
Q3 		$63.6K Buy
+2,323
New +$64.7K ﹤0.01% 2584
2024
Q2 		– Sell
-3,897
Closed -$117K – 5743
2024
Q1 		$117K Buy
3,897
+1,467
+60% +$31.9K ﹤0.01% 1746
2023
Q4 		$25.3K Buy
+2,430
New +$26.8K ﹤0.01% 3515
2023
Q3 		– Sell
-762
Closed -$9.24K – 5995
2023
Q2 		$9.24K Sell
762
-62
-8% -$705 ﹤0.01% 4314
2023
Q1 		$10K Sell
824
-1,602
-66% -$17.7K ﹤0.01% 4339
2022
Q4 		$15K Buy
2,426
+1,639
+208% +$29K ﹤0.01% 3409
2022
Q3 		$18K Buy
787
+30
+4% +$821 ﹤0.01% 4005
2022
Q2 		$15K Buy
757
+577
+321% +$14.3K ﹤0.01% 4063
2022
Q1 		$8K Sell
180
-1,584
-90% -$86.5K ﹤0.01% 4571
2021
Q4 		$125K Buy
1,764
+1,678
+1,951% +$169K ﹤0.01% 2077
2021
Q3 		$10K Sell
86
-538
-86% -$62.7K ﹤0.01% 4307
2021
Q2 		$97K Buy
624
+194
+45% +$35.6K ﹤0.01% 2449
2021
Q1 		$81K Buy
430
+334
+348% +$56.2K ﹤0.01% 2750
2020
Q4 		$12K Sell
96
-353
-79% -$40K ﹤0.01% 4193
2020
Q3 		$49K Sell
449
-53
-11% -$6.28K ﹤0.01% 3548
2020
Q2 		$61K Buy
502
+178
+55% +$25.1K ﹤0.01% 2891
2020
Q1 		$33K Buy
324
+285
+731% +$52.8K ﹤0.01% 1473
2019
Q4 		$9K Sell
39
-37
-49% -$6.91K ﹤0.01% 2378
2019
Q3 		$12K Buy
76
+68
+850% +$12.9K ﹤0.01% 2816
2019
Q2 		$2K Sell
8
-42
-84% -$10.4K ﹤0.01% 3250
2019
Q1 		$13K Buy
50
+37
+285% +$6.38K ﹤0.01% 2515
2018
Q4 		$1K Sell
13
-19
-59% -$2.59K ﹤0.01% 3568
2018
Q3 		$6K Buy
+32
New +$6.74K ﹤0.01% 3021

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Tower Research Capital (TRC)'s DNTH Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Dianthus Therapeutics (DNTH) stake by 61% in Q2 2026, selling an estimated $257K and leaving 1,845 shares worth $180K. The position accounts for ﹤0.01% of the portfolio, ranked #1773.

Tower Research Capital (TRC) first reported a position in DNTH in Q3 2018 and has held it in 29 quarters since. The position peaked at $402K in Q1 2026. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Tower Research Capital (TRC) held 1,845 shares of Dianthus Therapeutics worth $180K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,946 Dianthus Therapeutics shares in Q2 2026, an estimated $257K.
  • Dianthus Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1773 holding.
  • Tower Research Capital (TRC) first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 29 quarters since.
  • Tower Research Capital (TRC)'s Dianthus Therapeutics position peaked at $402K in Q1 2026.
  • 269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.